[go: up one dir, main page]

ATE162402T1 - Oraler an der oberfläche von erythrozyten gebundene antigene beinhaltender impfstoff - Google Patents

Oraler an der oberfläche von erythrozyten gebundene antigene beinhaltender impfstoff

Info

Publication number
ATE162402T1
ATE162402T1 AT91908727T AT91908727T ATE162402T1 AT E162402 T1 ATE162402 T1 AT E162402T1 AT 91908727 T AT91908727 T AT 91908727T AT 91908727 T AT91908727 T AT 91908727T AT E162402 T1 ATE162402 T1 AT E162402T1
Authority
AT
Austria
Prior art keywords
pct
erythrocytes
vaccine containing
oral vaccine
containing antigens
Prior art date
Application number
AT91908727T
Other languages
English (en)
Inventor
Gerald Toh Pang
Robert Llewellyn Clancy
Original Assignee
Flustat Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flustat Pty Ltd filed Critical Flustat Pty Ltd
Application granted granted Critical
Publication of ATE162402T1 publication Critical patent/ATE162402T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6006—Cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT91908727T 1990-04-24 1991-04-24 Oraler an der oberfläche von erythrozyten gebundene antigene beinhaltender impfstoff ATE162402T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPJ978390 1990-04-24

Publications (1)

Publication Number Publication Date
ATE162402T1 true ATE162402T1 (de) 1998-02-15

Family

ID=3774614

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91908727T ATE162402T1 (de) 1990-04-24 1991-04-24 Oraler an der oberfläche von erythrozyten gebundene antigene beinhaltender impfstoff

Country Status (14)

Country Link
US (1) US5643577A (de)
EP (1) EP0528859B1 (de)
JP (1) JPH05506233A (de)
KR (1) KR100186783B1 (de)
AT (1) ATE162402T1 (de)
AU (1) AU646257B2 (de)
BR (1) BR9106374A (de)
CA (1) CA2080477A1 (de)
DE (1) DE69128782T2 (de)
DK (1) DK0528859T3 (de)
ES (1) ES2113882T3 (de)
GR (1) GR3026569T3 (de)
SG (1) SG46225A1 (de)
WO (1) WO1991016073A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882649A (en) * 1990-04-24 1999-03-16 Flustat Pty. Ltd. Oral vaccine comprising antigen surface-associated with red blood cells
GB2294268A (en) 1994-07-07 1996-04-24 Procter & Gamble Bleaching composition for dishwasher use
GB9517269D0 (en) * 1995-08-23 1995-10-25 Cortecs Ltd Vaccines
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US5993852A (en) * 1997-08-29 1999-11-30 Pharmaderm Laboratories Ltd. Biphasic lipid vesicle composition for transdermal administration of an immunogen
EP1030572A1 (de) 1997-11-21 2000-08-30 The Procter & Gamble Company Produktauftragegerät
GB2369094A (en) 2000-11-17 2002-05-22 Procter & Gamble Packaging assembly for sheets of water-soluble sachets
WO2002060416A1 (en) * 2001-02-01 2002-08-08 Gendel Limited Polypeptide delivery system and method for their preparation
US20060083702A1 (en) * 2004-04-02 2006-04-20 Thomas Fondin Hair fiber treating method
WO2006068306A2 (en) 2004-12-22 2006-06-29 Fujifilm Corporation COMPOSITION FOR STERILIZATION COMPRISING ω-ALKOXYPEROXYCARBOXYLIC ACID
US8318912B2 (en) * 2006-06-23 2012-11-27 Augmenta Biologicals, Llc Targeted immune conjugate comprising an antibody to glycophorin A and a M2e peptide
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
WO2010009271A2 (en) 2008-07-15 2010-01-21 Academia Sinica Glycan arrays on ptfe-like aluminum coated glass slides and related methods
GB0901207D0 (en) 2009-01-26 2009-03-11 Innospec Ltd Chelating agents and methods relating thereto
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
WO2011138032A2 (en) 2010-05-05 2011-11-10 Artemev, Timur Universal influenza vaccines and methods for their generation
AR083533A1 (es) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
WO2012059112A1 (en) * 2010-11-01 2012-05-10 Mahmoud Abdel Wahed Rafea Development of medical products based on a new discovered function of red blood cells
CN107115314B (zh) * 2011-06-02 2022-04-29 加利福尼亚大学董事会 膜包封的纳米颗粒及使用方法
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
CN103987836B (zh) 2011-10-17 2018-04-10 麻省理工学院 细胞内传递
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
US9914956B2 (en) 2012-08-18 2018-03-13 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
MX360137B (es) 2013-02-21 2018-10-24 Boehringer Ingelheim Vetmedica Gmbh Proteínas h5 del virus de la influenza h5n1 para usarse como un medicamento.
EP3013365B1 (de) 2013-06-26 2019-06-05 Academia Sinica Rm2-antigene und verwendung davon
EP3013347B1 (de) 2013-06-27 2019-12-11 Academia Sinica Glykankonjugate und verwendung davon
JP6502940B2 (ja) 2013-08-16 2019-04-17 マサチューセッツ インスティテュート オブ テクノロジー 細胞への物質の選択的送達
CA2923579C (en) 2013-09-06 2023-09-05 Academia Sinica Human inkt cell activation using glycolipids with altered glycosyl groups
AU2015206370A1 (en) 2014-01-16 2016-07-07 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
JP6562942B2 (ja) 2014-03-27 2019-08-28 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 反応性標識化合物およびその使用
DK3149045T3 (da) 2014-05-27 2023-03-06 Academia Sinica Sammensætninger og fremgangsmåder vedrørende universelle glycoformer til forbedret antistofeffekt
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR20220151036A (ko) 2014-05-27 2022-11-11 아카데미아 시니카 항-ｃｄ20 글리코항체 및 이의 용도
US10005847B2 (en) 2014-05-27 2018-06-26 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
AU2015267044A1 (en) 2014-05-28 2016-12-15 Academia Sinica Anti-TNF-alpha glycoantibodies and uses thereof
WO2016040369A2 (en) 2014-09-08 2016-03-17 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
RU2739794C2 (ru) 2014-10-31 2020-12-28 Массачусетс Инститьют Оф Текнолоджи Доставка биомолекул в клетки иммунной системы
WO2016077761A1 (en) 2014-11-14 2016-05-19 Massachusetts Institute Of Technology Disruption and field enabled delivery of compounds and compositions into cells
AU2016206870B2 (en) 2015-01-12 2022-02-17 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
TWI736523B (zh) 2015-01-24 2021-08-21 中央研究院 新穎聚醣結合物及其使用方法
CN107922911A (zh) 2015-07-09 2018-04-17 麻省理工学院 将物质递送至无核细胞
US11613759B2 (en) 2015-09-04 2023-03-28 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
AU2017231749A1 (en) 2016-03-08 2018-09-20 Academia Sinica Methods for modular synthesis of N-glycans and arrays thereof
CN109963868B (zh) 2016-08-22 2023-11-14 醣基生医股份有限公司 抗体、结合片段及使用方法
JP2025539614A (ja) 2022-12-16 2025-12-05 インノスペック リミテッド 微粒子組成物
GB202409569D0 (en) 2024-07-02 2024-08-14 Innospec Performance Chemicals Italia Srl Compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136167A (en) * 1975-06-12 1979-01-23 Internationale Octrooi Maatschappij "Octropa" B.V. Process for reducing the incidence of neonatal diarrhoea in pigs
DE2551208C3 (de) * 1975-11-14 1981-05-27 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung einer stabilen Erythrozyten-Präparation
FR2355507A1 (fr) * 1976-06-25 1978-01-20 Inst Nat Sante Rech Med Vaccin antiparasitaire par voie orale, son procede de preparation et sa methode d'application chez les mammiferes
SU649435A1 (ru) * 1977-06-24 1979-02-28 Уфимский Научно-Исследовательский Институт Вакции И Сывороток Им. И.И.Мечникова Способ приготовлени эритроцитов
US4403037A (en) * 1980-10-10 1983-09-06 American Hoechst Corporation Erythrocyte preparations and use thereof in hemagglutination tests
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4904468A (en) * 1987-06-08 1990-02-27 Norden Laboratories, Inc. Canine coronavirus vaccine

Also Published As

Publication number Publication date
EP0528859B1 (de) 1998-01-21
CA2080477A1 (en) 1991-10-25
AU7753191A (en) 1991-11-11
JPH05506233A (ja) 1993-09-16
SG46225A1 (en) 1998-02-20
KR100186783B1 (ko) 1999-05-01
WO1991016073A1 (en) 1991-10-31
AU646257B2 (en) 1994-02-17
BR9106374A (pt) 1993-03-30
DE69128782D1 (de) 1998-02-26
EP0528859A4 (en) 1993-08-04
GR3026569T3 (en) 1998-07-31
DK0528859T3 (da) 1998-09-14
HK1004060A1 (en) 1998-11-13
US5643577A (en) 1997-07-01
ES2113882T3 (es) 1998-05-16
DE69128782T2 (de) 1998-09-10
EP0528859A1 (de) 1993-03-03

Similar Documents

Publication Publication Date Title
ATE162402T1 (de) Oraler an der oberfläche von erythrozyten gebundene antigene beinhaltender impfstoff
DE69534992D1 (de) Mutierendes enterotoxin als nichttoxisches orales adjuvans
DK257485A (da) Farmaceutiske praeparater til oral indgift
AR063315A2 (es) Composicion que comprende un virus, y metodos para concentrar y purificar preparados de virus
ES2118963T3 (es) Vacunas combinadas, que contienen antigeno de superficie de la hepatitis b y otros antigenos.
IT1236688B (it) Procedimento e dispositivo per la creazione di una miscela combustibile-aria comburente da addurre a una combustione.
AU2684792A (en) Porcine reproductive respiratory syndrome vaccine and diagnostic
DE69943170D1 (de) Immunologische Zusammensetzung und Impfstoffe, die einen auf N-Formyl-Methionyl Peptide bestehenden Adjuvans enthalten
ATE105334T1 (de) Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
DE3485873D1 (en) Herpes simplex virus subunitimpfstoff.
ES2044849T3 (es) Un procedimiento para preparar un glicosido de flavona.
NO940661L (no) Peptider for indusering av cytotoksisk T-lymfocytreaksjoner mot hepatit B virus
DK482185D0 (da) Peptider, deres fremstilling og anvendelse som laegemidler
SE8303401D0 (sv) Beredning och dess anvendning
HK141494A (en) Peptide fragments of HIV
DK384088A (da) Substituerede benzimidazoler, deres fremstilling, praeparater indeholdende disse samt deres anvendelse som laegemidler
DE3864261D1 (de) Beschichtete gegenstaende aus nahezu alpha-titanium.
FI923020A0 (fi) Inte a inte b-sekvenser.
IT1177147B (it) Composizione farmaceutica per combattere infezioni virali, e procedimento di uso per le infezioni virali
EP0090660A3 (de) Neisseria Gonorrhöe Vakzin
ATE18007T1 (de) Hepatitisimpfstoff.
NO913131L (no) Immunogene konjugater av ikke-toksisk oligosakkarid fra bordetella pertussis lipoolysakkarid.
GB9106278D0 (en) Method of treatment
FI872363A7 (fi) Bakteriosiinit ja niitä sisältävät koostumukset virusinfektioiden detektioon ja hoitoon.
ES2062502T3 (es) Una proteina de factor i pura y un procedimiento para obtener dicha proteina.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee